Lenvatinib (LEN) plus pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.

被引：0
|
作者：
Lee, Chung-Han
Shah, Amishi Yogesh
Hsieh, James J.
Rao, Arpit
Pinto, Alvaro
Bilen, Mehmet Asim
Cohn, Allen Lee
DiSimone, Christopher
Shaffer, David R.
Sarrio, Regina Girones
Ribe, Sara Gunnestad
Wu, Jane
Schmidt, Emmett V.
Kubiak, Peter
Okpara, Chinyere
Smith, Alan D.
Motzer, Robert J.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, Dept Med, Oncol Div, St Louis, MO 63110 USA
[4] South Texas Accelerated Res Therapeut, Dept Clin Res, San Antonio, TX USA
[5] Hosp Univ La Paz, Serv Oncol, Madrid, Spain
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[7] US Oncol Res, Rocky Mt Canc Ctr, Med Oncol, Denver, CO USA
[8] Arizona Oncol Associates, Med Oncol Hematol, Tucson, AZ USA
[9] New York Oncol Hematol, US Oncol Res, Med Oncol, Albany, NY USA
[10] Hosp Univ & Politecn FE, Med Oncol Serv, Valencia, Spain
[11] Sorlandet Hosp Kristiansand, Med Oncol, Kristiansand, Norway
[12] Eisai Inc, Biostat, Woodcliff Lake, NJ USA
[13] Merck & Co Inc, Clin Res, Kenilworth, NJ USA
[14] Eisai Inc, Clin Res, Woodcliff Lake, NJ USA
[15] Eisai Ltd, Clin Res, Hatfield, Herts, England
[16] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16542
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
    Taylor, M.
    Dutcus, C. E.
    Schmidt, E.
    Bagulho, T.
    Li, D.
    Shumaker, R.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
    Lee, C-H.
    Shah, A. Y.
    Hsieh, J. J.
    Rao, A.
    Pinto, A.
    Bilen, M. A.
    Cohn, A. L.
    Di Simone, C.
    Shaffer, D. R.
    Girones Sarrio, R.
    Ribe, S. Gunnestad
    Wu, J.
    Schmidt, E.
    Kubiak, P.
    Okpara, C. E.
    Smith, A. D.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S558 - S559
  • [23] A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari D.
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kraljevic, Silvija
    Ishikawa, Kohei
    Siegel, Abby B.
    Kumada, Hiromitsu
    Young, Louise
    Okusaka, Takuji
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 105 - 105
  • [24] A Phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, M.
    Sung, M. W.
    Kudo, M.
    Kobayashi, M.
    Baron, A. D.
    Finn, R. S.
    Kaneko, S.
    Zhu, A. X.
    Kubota, T.
    Kraljevic, S.
    Ishikawa, K.
    Siegel, A. B.
    Kumada, H.
    Okusaka, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 37 - 37
  • [25] Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
    Keeler, Molika Emmeline
    Kessler, Elizabeth Riley
    Bernard, Brandon
    Weisdack, Sarah
    Breaker, Kathryn M.
    Wold, Mali
    Ertz, Donna
    Weitzenkamp, David
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [26] Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN plus EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Motzer, Robert
    Hutson, Thomas
    Glen, Hilary
    Michaelson, Dror
    Molina, Ana M.
    Eisen, Timothy
    Jassem, Jacek
    Zolnierek, Jakub
    Maroto, Pablo
    Mellado, Begona
    Melichar, Bohuslav
    Tomasek, Jiri
    Kim, Han-Joo
    Wood, Karen
    Dutcus, Corina
    Larkin, James M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Lee, Chung-Han
    Shah, Amishi Y.
    Makker, Vicky
    Taylor, Matthew
    Shaffer, David
    Hseih, James J.
    Cohn, Allen L.
    Di Simone, Chris
    Marin, Alvaro Pinto
    Rasco, Drew
    Gunnestad-Ribe, Sara
    Richards, Donald A.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Wu, Jane
    Schmidt, Emmett V.
    Perini, Rodolfo
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 101 - 102
  • [28] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Matthew
    Dutcus, Corina
    Shumaker, Robert
    Schmidt, Emmett
    Stepan, Daniel E.
    Li, Di
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
  • [29] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Mathew
    Stepan, Daniel E.
    Shumaker, Robert
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 175
  • [30] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
    Lee, Chung-Han
    Voss, Martin H.
    Carlo, Maria Isabel
    Chen, Ying-Bei
    Reznik, Eduard
    Knezevic, Andrea
    Lefkowitz, Robert A.
    Shapnik, Natalie
    Tassone, Diana
    Dadoun, Chloe
    Shah, Neil J.
    Owens, Colette Ngozi
    McHugh, Deaglan Joseph
    Aggen, David Henry
    Laccetti, Andrew Leonard
    Kotecha, Ritesh
    Feldman, Darren R.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345